WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 300143
CAS#: 103060-53-3
Description: Daptomycin is a novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms. It is a naturally occurring compound found in the soil saprotroph Streptomyces roseosporus. Its distinct mechanism of action means that it may be useful in treating infections caused by multi-resistant bacteria. It is marketed in the United States under the trade name Cubicin by Cubist Pharmaceuticals.
MedKoo Cat#: 300143
Name: Daptomycin
CAS#: 103060-53-3
Chemical Formula: C72H101N17O26
Exact Mass: 1619.71037
Molecular Weight: 1620.67
Elemental Analysis: C, 53.36; H, 6.28; N, 14.69; O, 25.67
Synonym: LY 146032; LY-146032; LY146032; Daptomycin; Cidecin; Cubicin;
IUPAC/Chemical Name: 2,2'-((3S,6S,9R,15S,18R,21S,24S)-30-((S)-2-((S)-4-amino-2-((S)-2-decanamido-3-(1H-indol-3-yl)propanamido)-4-oxobutanamido)-3-carboxypropanamido)-3-(2-(2-aminophenyl)-2-oxoethyl)-24-(3-aminopropyl)-6-((R)-1-carboxypropan-2-yl)-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaazacyclohentriacontane-15,21-diyl)diacetic acid
InChi Key: DOAKLVKFURWEDJ-AVSAZHKKSA-N
InChi Code: InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37?,43+,44+,45+,46+,47+,48+,49+,50-,60+,61?/m1/s1
SMILES Code: O=C1NCC(N[C@@H](CCCN)C(N[C@@H](CC(O)=O)C(N[C@H](C)C(N[C@@H](CC(O)=O)C(NCC(N[C@H](CO)C(N[C@@H]([C@H](C)CC(O)=O)C(N[C@@H](CC(C2=CC=CC=C2N)=O)C(OC(C)C1NC([C@@H](NC([C@@H](NC([C@@H](NC(CCCCCCCCC)=O)CC3=CNC4=C3C=CC=C4)=O)CC(N)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Appearance: solid powder
Purity: >94% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 1620.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tirilomis T. Daptomycin and Its Immunomodulatory Effect: Consequences for Antibiotic Treatment of Methicillin-Resistant Staphylococcus aureus Wound Infections after Heart Surgery. Front Immunol. 2014 Mar 11;5:97. doi: 10.3389/fimmu.2014.00097. eCollection 2014. Review. PubMed PMID: 24653723; PubMed Central PMCID: PMC3949290.
2: Kelesidis T. The Interplay between Daptomycin and the Immune System. Front Immunol. 2014 Feb 12;5:52. doi: 10.3389/fimmu.2014.00052. eCollection 2014. Review. PubMed PMID: 24575098; PubMed Central PMCID: PMC3921582.
3: Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013 Oct;26(4):759-80. doi: 10.1128/CMR.00030-13. Review. PubMed PMID: 24092854; PubMed Central PMCID: PMC3811228.
4: Whang DW, Miller LG, Partain NM, McKinnell JA. Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections. Antimicrob Agents Chemother. 2013 Oct;57(10):5013-8. doi: 10.1128/AAC.00714-13. Epub 2013 Jul 29. Review. PubMed PMID: 23896468; PubMed Central PMCID: PMC3811395.
5: Shukla BS, Gauthier TP, Correa R, Smith L, Abbo L. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. Int J Clin Pharm. 2013 Oct;35(5):697-703. doi: 10.1007/s11096-013-9825-5. Epub 2013 Jul 27. Review. PubMed PMID: 23893061.
6: Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents. 2013 Sep;42(3):202-10. doi: 10.1016/j.ijantimicag.2013.05.005. Epub 2013 Jul 8. Review. PubMed PMID: 23845504.
7: Gilmore JF, Kim M, LaSalvia MT, Mahoney MV. Treatment of enterococcal peritonitis with intraperitoneal daptomycin in a vancomycin-allergic patient and a review of the literature. Perit Dial Int. 2013 Jul-Aug;33(4):353-7. doi: 10.3747/pdi.2012.00277. Review. PubMed PMID: 23843587; PubMed Central PMCID: PMC3707710.
8: Phillips J, Cardile AP, Patterson TF, Lewis JS 2nd. Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports. Scand J Infect Dis. 2013 Oct;45(10):804-8. doi: 10.3109/00365548.2013.805427. Epub 2013 Jul 5. Review. PubMed PMID: 23826793.
9: Di Carlo P, D'Alessandro N, Guadagnino G, Bonura C, Mammina C, Lunetta M, Novo S, Giarratano A. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Infez Med. 2013 Mar;21(1):45-9. Review. PubMed PMID: 23524901.
10: Kanzler I, Weis F, Beiras-Fernandez A. Current use of daptomycin in cardiac surgery and postoperative intensive care. Expert Rev Anti Infect Ther. 2013 Mar;11(3):309-20. doi: 10.1586/eri.13.3. Review. PubMed PMID: 23458770.
